Authors

• Markus Reuber (ORCID: https://orcid.org/0000-0002-4104-6705)
• Marie Le Novere (ORCID: https://orcid.org/0000-0002-9479-8599)
• Jon Stone (ORCID: https://orcid.org/0000-0001-9829-8092)
• Jonathan Marsden (ORCID: https://orcid.org/0000-0002-2037-4902)
• Laura H. Goldstein (ORCID: https://orcid.org/0000-0001-9387-3035)
• Teresa Lee (ORCID: https://orcid.org/0009-0009-0917-860X)
• Irwin Nazareth (ORCID: https://orcid.org/0000-0003-2146-9628)
• Alan Carson (ORCID: https://orcid.org/0000-0002-7425-0964)
• Rachael Hunter (ORCID: https://orcid.org/0000-0002-7447-8934)
• Louise Marston (ORCID: https://orcid.org/0000-0002-9973-1131)
• Hayley Noble (ORCID: https://orcid.org/0000-0002-4267-1609)
• Mark John Edwards (ORCID: https://orcid.org/0000-0002-8283-9015)
• Glenn Nielsen (ORCID: https://orcid.org/0000-0001-6053-5670)
• Beatriz Santana Suárez (ORCID: https://orcid.org/0000-0002-1902-8332)
• Kate Holt (ORCID: https://orcid.org/0009-0003-9529-2420)
• Ann-Marie Strudwick (ORCID: https://orcid.org/0000-0003-2817-5219)

Institutions

• St George's, University of London (GB)
• King's College London (GB)
• Edinburgh Royal Infirmary (GB)
• MRC Clinical Trials Unit at UCL (GB)
• Maudsley Hospital (GB)
• Clarivate (United States) (US)
• King's College Hospital (GB)
• University College London (GB)
• University of Plymouth (GB)
• University of Sheffield (GB)

Publication Details

Journal

Neurology Clinical Practice

Published

2025-04-03

DOI

https://doi.org/10.1212/cpj.0000000000200465

Citations

1

Primary Topic

Psychosomatic Disorders and Their Treatments

Type

article

Field-Weighted Citation Impact

1.47

Funders

• Teva Pharmaceutical Industries
• Wellcome Trust
• UK Research and Innovation
• National Institute for Health and Care Research
• Department of Health and Social Care
• Epilepsy Research UK
• University of Oxford
• European Commission
• Angelini Pharma
• Medical Research Council
• UCB Pharma